Contents

Volume 2, Issue 7 July 2020

COLUMNS
SENSORY SCIENCE …….………………………………………….….……….……………………………………………………………………….4
Decoding the sense of smell: understanding the structural organization within the brain
https://doi.org/10.37756/bk.20.2.7.1
SEQUENCING ………………….………………….……………….………………………………….. …………………………………………….10
Next Generation Sequencing Technology in Clinical Diagnostics
https://doi.org/10.37756/bk.20.2.7.2
SENOLYTICS AND HEALTHY LIFESPANS…….……………….…………………………………………………………………………18
Senolytics for Therapeutic Interventions for Reverse Aging and Extended Healthy
Lifespans
https://doi.org/10.37756/bk.20.2.7.3
BIOTECH R&D AND INNOVATION NEWS…………………………………….……………….……………………………………………………25
Editor’s PICKS: Biotechnology Advances around the World
Alzheimer’s Disease………………………………………………….……………………………………………………………………………………26
Anti-Aging Drugs.……………………………………………………………….……….……………………………………………………………..27
Tuberculosis and Antibiotics.…………………………………………………….….……………………………………………………………..28
Stem Cells and Regenerative Therapies….……..…………………………………………………………………………………………….29
BIOTECH AND PHARMA INDUSTRY ROUNDUP..……………………………………….……………………………………………………….31
CytoSorbents got awarded $4.4 Million for Universal Plasma Product………………………………………………………31
Sangamo, Novartis join hands to develop genetic medicines for autism…………………………………………………..31
Supply of Gilead’s COVID-19 drug remdesivir secured by Europe…………………………………………………………….31
Eastman Kodak to help manufacturing drugs, vaccines in the US…………………………………………………………….31
AlloVir Raises $276 Million to Advance Cell Therapy Programs…………………………………………………………………32
GSK and Sanofi deal with U.S. Government for COVID-19 Vaccine……………….….………………………………………..32
COVID-19 Vaccine Candidate into Phase I by Merck in Q3………………………………………………………………………..32
Roche’s IL-6 receptor blocker fails in Phase III trial………………………………………………………………………………..33
COVID-19 vaccine by Pfizer and BioNTech’s shows positive data ….………….….………………………………………..33
A New H1N1 Strain can trigger another global pandemic.……………………….…….……………………………………………33
ZILXI™ (minocycline), receives FDA approval for rosacea………………………………………………………………………….33
Meningococcal Vaccines expected to touch USD 9 billion by 2026 ………………………………………………………….34
Price set for COVID-19 drug remdesivir…………………………………………………….……………………………………………………34
WHO plan to deliver 2 billion coronavirus vaccine doses……………………………………………………………………………34
Large scale phase 2 & 3 trials are underway for coronavirus vaccine………………………………………………………..34
Investments to counter Cancer genes………………………………….…………………………………………………………………….35
EC pledges €4.9bn to grant access to medicines……………………………………………………………………………………………35
No beneficial effect of lopinavir-ritonavir on COVID-19 patients ……………….……….…………………………………….35
HALIX B.V. to produce vaccines against COVID-19……………………………………………………………………………………………35
SARS-CoV2 antibody tests might not be suitable for individual diagnosis……………………………………………………35
Enthera Pharmaceuticals Srl secures €28m in Series A financing………………………………………………………………..35